We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01813487
Recruitment Status : Completed
First Posted : March 19, 2013
Last Update Posted : December 30, 2013
Sponsor:
Information provided by (Responsible Party):
Genexine, Inc.

Brief Summary:
The purpose of this study is to examine the immunogenicity and efficacy of HBsAg Vaccine in combination with Entecavir in patients who have been treated with HB110E HBV DNA vaccine.

Condition or disease Intervention/treatment
Chronic Hepatitis B Drug: HBsAg vaccine with Entecavir

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy in Patients Who Have Been Treated With HB110E Hepatitis B DNA Vaccine
Study Start Date : February 2013
Primary Completion Date : July 2013
Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Entecavir
U.S. FDA Resources

Arm Intervention/treatment
HBsAg vaccine with Entecavir Drug: HBsAg vaccine with Entecavir



Primary Outcome Measures :
  1. Immunogenicity: HBV specific T-cell response by ELISPOT [ Time Frame: Change from Baseline in HBV specificic T-cell response at 16 weeks ]
    sample for immunologic assay will be collected at each visit; VS(~4week), VT1(0week), VT2(8week), VF(16week. T-cell response will be measured by ex-vivo & cultured ELISPOT.


Secondary Outcome Measures :
  1. HBsAg titer [ Time Frame: Change from baseline in HBsAg titer at 16 weeks ]
    sample for HBsAg will be collected at each visit; VS(~4week), VT1(0week), VT2(8week), VF(16week. Change from baseline in HBsAg titer will be measured at VF.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • subjects who have been treated with HB110E 2mg or 4mg within 6 months prior to screening.
  • positive HBsAg at screening
  • serum HBV DNA level below 300copies/mL at screening
  • ALT level within 2 x ULN at screening
  • voluntarily provide the informed consent

Exclusion Criteria:

  • participation in other study within 30 days of screening
  • subjects with severe allergic reaction or severe adverse event to HBsAg vaccine, or not suitable for HBsAg vaccine.
  • any other conditions that are considered inappropriate for the study by the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01813487


Locations
Korea, Republic of
The Catholic University of Korea Seoul St. Mary's Hospital
Seoul, Korea, Republic of, 137 701
Sponsors and Collaborators
Genexine, Inc.
Investigators
Principal Investigator: Seung Yoon, MD The Catholic University of Korea

Responsible Party: Genexine, Inc.
ClinicalTrials.gov Identifier: NCT01813487     History of Changes
Other Study ID Numbers: HB110E_PI_PS
First Posted: March 19, 2013    Key Record Dates
Last Update Posted: December 30, 2013
Last Verified: December 2013

Additional relevant MeSH terms:
Hepatitis
Hepatitis, Chronic
Hepatitis B
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human
Vaccines
Antiviral Agents
Entecavir
Immunologic Factors
Physiological Effects of Drugs
Anti-Infective Agents